Results from the PCCTC's STREAM Study Led by Rhonda L Bitting, MD of Duke University Published

Study shows that LD and higher ADT sensitivity tumors had favorable outcomes. Those with a luminal proliferating subtype, PTEN loss, and/or HRD signatures had poor outcomes despite ADT/radiation and enzalutamide and may benefit from alternative approach.